KRAS and neoplasm: In the largest study to date to associate tumor-specific genetic aberrations with VTE (n = 11,695), Dunbar et al described a link between increased VTE risk in patients with solid tumors and tumor mutations inSTK11,CDKN2B,KEAP1,KRAS,CTNNB1, andMET.